AI assistant
SOLARA ACTIVE PHARMA SCIENCES LIMITED Interim / Quarterly Report 2025
61842_rns_2025-07-26_e2994591-fc65-4e23-a610-91beaa39d058.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Corporate Office:
TICEL Bio Park, 6th Floor, i 4 Active Pharma Sciences Module No. 601, 602, 603, Phase II — CSIR Road, Taramani, Chennai, Tamil Nadu — 600113. Tel: +91 44 47406200 Fax: +91 44 47406190 E-mail: [email protected] Website: www.solara.co.in
July 26, 2025
| The BSE Limited | The National Stock Exchange of India |
|---|---|
| Phiroze Jeejeebhoy Towers | Limited |
| Dalal Street, Mumbai — 400 001 | Exchange Plaza, C-1, Block G, Bandra-Kurla |
| Complex, Bandra (E), Mumbai — 400 051 |
Scrip Code: 541540, 890202 Scrip Code: SOLARA, SOLARAPP1
Dear Sir/Madam,
Sub: Newspaper advertisement — unaudited Financial Results for the quarter ended June 30, 2025.
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of newspaper advertisement published on July 26, 2025, in the 'Business Standard' and 'Pratahkal' providing extract of the unaudited Financial Results for the quarter ended June 30, 2025.
These are also being made available on the Company's website at https://solara.co.in/investorrelations/newspaper-publications.
This is for your information and record.
Thanking you,
Yours faithfully, For Solara Active Pharma Sciences Limited
Encl.: as above
Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636
Pooja Jayakumar Company Secretary and Compliance Officer ICSI Membership No.: A57415 Registered Office: 9" Floor, 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91-22-2789 2924 POOJA JAYA
KUMAR Digitally signed by POOJA JAYA KUMAR Date: 2025.07.26 16:29:39 +05'30'
Cipla Limited Cipla
CIN: L24239MH1935PLC002380
Regd. Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013. Tel. No.: (022) 4191 6000 + Fax No.: (022) 4191 6120 + E-mail: [email protected] + Website: www.cipla.com
UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30™ JUNE, 2025
In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of the Cipla Limited ("Company") at its meeting held on Friday, 25" July, 2025 approved the unaudited financial results (standalone and consolidated) for the quarter ended 30" June, 2025 ("results").
SOLARA ACTIVE PHARMA SCIENCES LIMITED a e " SOLARA 6: 24230mH2017PLc291636
Ng Aetive Pharma Sciences Regd. Office: 9th Floor, "Cyber One", Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 Tel: +91-22-2789 2924
Corporate Office: TICEL BIO PARK, 6th floor Module No. 601, 602, 603, Phase Il - CSIR Road, Taramani, Chennai, Tamil Nadu — 600113. Tel: +91 44 4344 6700 | Fax: +91 44 47406190 | E-mail: [email protected], www.solara.co.in
The results, along with the limited review report (standalone and consolidated) by M/s. Walker Chandiok & Co LLP, Statutory Auditor of the Company are available on the website of the Company at www.cipla.com/investors/quarterlyresults, and on websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025
| in Crores except per share data) | ||
|---|---|---|
In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can also be accessed by scanning the following Quick response (QR) code:
For CIPLA LIMITED
Sdi-
Rajendra Chopra
Company Secretary
ACS A12011
T-/3 Date: 25" July, 2025 AZ Place: Mumbai
CYIENT Cyient Limited, Regd. Office: 4th Floor, 'A' Wing, Plot No. 11, Software Units Layout, Infocity, Madhapur, Hyderabad - 500 081, India Ph: 040 - 67641322, Email: [email protected], Website: www.cyient.com CIN: L72200TG1991PLC013134 in Millions)
| Statement of Unaudited Consolidated and Standalone Financial Results for the Quarter Ended June 30, 2025 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Consolidated Results | ||||||||
| [Gunteended GurecEned [Wer Ened GuwterEned [Gua ended [Yew eno | ||||||||
| ZT | pe | sovun-2s soun-24 31-ar25 | oa] | |||||
| nes po | ees | |||||||
| [+ Revue fom contacts wth customers | [ | se06 24.198 | ||||||
| Net Prof forthe period (before Tax and/or Exceptional items) |
||||||||
| [Net Profit forthe period after tax (after Exceptional iters) Attributable to: |
||||||||
| Shareholders of the Company | ||||||||
| Non-controling interests | ||||||||
| 'Total Comprehensive Income for the period | ||||||||
| Attributable to: 'Shareholders of the Company |
||||||||
| 'Non-controlling interests | — | |||||||
| 6 Eamings Per Share [Face Value of & 5 per share] | ||||||||
| [roses int | a9 | |||||||
| *EPS for the quarters are not annualised, NOTES : 1, The unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on July 23, 2025 and July 24, 2025, respectively. The Statutory Auditors have expressed an unmodified opinion on the unaudited consolidated and standalone financial results. 2. The above financial results are an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, The full format of the quarterly financial results Is available on the Stock Exchange websites: www.bseindia.com and www.nseindia.com, and also on the Company's website: www.cyient.com. The same can also be accessed by scanning the QR code provided below. |
||||||||
| For CYIENT LIMITED Sd/- KRISHNA BODANAPU and Managing Director Executive Vice Chairman |
| Particulars | a months | Preceding 3 months ended |
Correspondin: Smonths ended in the previous year |
Previous Financial Year ended |
|---|---|---|---|---|
| 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 | |
| UNAUDITED | UNAUDITED | |||
| Total income 'fom 'operations | ||||
| Net Profit for the period before tax (before exceptional items) | ||||
| Net Profit for the p od or Ore {after exceptional items) | ||||
| Other Cote ee | ||||
| the period | ||||
| ae 'Comprehensive Income for the period (4 + 5) Equit a Capital |
||||
| Earrings Per Share (of Rs. 10/- each) | ||||
| {for continuing operations) - | ||||
| Basic (Rs. | ||||
| 8 | |||||||
|---|---|---|---|---|---|---|---|
| LAURUS Labs | |||||||
| Ae Chemistry for Better Living |
|||||||
| Laurus Labs | Limited | ||||||
| (CIN: L24239AP2005PLC047518) | |||||||
| Regd.Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021, India | |||||||
| Corp.Office: 2nd Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad - 500034, Telangana, India | |||||||
| Tel: +91 040 3980 4333 ; Fax: +91 040 3980 4320 ; E-mail: [email protected] ; Website: www.laurusiabs.com | |||||||
| Extract of Consolidated Unaudited Financial results for the quarter ended June 30, 2025 which are prepared in compliance with Indian Accounting Standards. |
|||||||
| (in Crores) | |||||||
| [as [seas [oem | srs | ||||||
| fom | [ume [ue | tr | ct |
||||
| [ss |
|||||||
| Net Profit for the period (before tax, Exeeional and/or Extraordinary items) |
2 22 | ||||||
| Net Profit for the period before tax (after Exceptional and/or Extraordinary items) |
|||||||
| = ae a 3.0 Net Profit for the period after tax (after Exceptional and/or Extraordinary items) |
161.68 EC |
23; | [mse 12.68 |
||||
| [5 | Total Comprehensive income forthe period | ||||||
| {after Exceptional and/or Extraordinary items) attributable to: | |||||||
| C= 807.96 [i Eauty holders ofthe Company |
fs | 7 |
asi 25032 _ | ||||
| [ i) Non-controling interests | ey | 0.90) | 0.02 | ||||
| tee [Total Comprehensive Income ortheparodatibuabete |
za sy fen e | ||||||
| JL | a lr of te Compary |
DS sh |
Ce a | ||||
| [8 | |||||||
| [Equity Share Capital |
a | ||||||
| interests as shown in the Audited Balance Sheet | T4423 | ||||||
| Jd | _10 Eamings Per Share (of €2/-each) | 65 | |||||
| J [2 | a. Basics ee dilutedsee |
||||||
| * Not annualised for quarter ended. | |||||||
| Notes: | |||||||
| 1. Additional information on Standalone Unaudited financial results for the quarter ended June 30, 2025 | 'in Crores) | ||||||
| i | ortheperod_———S~S~S | __ 211.44 330.20 | _ 1650.01 1,116.93 | ||||
| 12 3 |
[___251.90_ | __503.81_ | |||||
| [4 [Tota Comprehensive income |
SC | 25029 | 29.08 379.63 _ | ||||
| 2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly www.nseindia.com and www.lauruslabs.com. The same can be accessed by scanning the Financial Results are available on the websites of the Stock Exchanges and the Company namely www.bseindia.com, QR code provided below. |
|||||||
| The above financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. Place: Hyderabad |
By order of the Board For Laurus Labs Limited Sd/- Dr. Satyanaray: |
||||||
| Date : July 25, 2025 | Whole Time Director & |
1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEB! Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the National Stock Exchange of India Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)
2 The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company" and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. The results for the quarter ended June 30, 2025 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company, The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter ended June 30, 2025.
3 The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 partly paid equity shares of face value of Rs. 10/- each ata price of Rs. 375 per
Equity share (including Share premium of Rs. 365 per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record datei.e May 15, 2024. Rightsissue has been done in accordance with Section 62(1)(a) of the Companies Act and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on June 19, 2024.
'On March 26, 2025, the Company, approved the Rights Issue First Call of Rs.131.25 per Rights Share (Rs. 3.50 face value and Rs. 127.75 Share premium) for 1,19,98,755 partly paid Rights Shares, as per the Letter of Offer dated May 09, 2024. The First Call payment window was open from April 16, 2025 to April 30, 2025. The Rights Issue Committee on May 06, 2025, took note of receipt of First call money amounting Rs.149.49 Crores and approved conversion of 1,13,89,767 partly paid shares of Rs. 3.5 per share to partly paid of Rs. 7 per share,
Out of net proceeds from First Call money, Rs. 115.00 crores is used against repayment of borrowings, Rs.23.27 crores towards general corporate purposes inline with terms of utilization mentioned in letter of offer.
4 The Board of Directors of the Parent at its meeting held on January 24, 2025 had discussed a proposal to explore 'demerger of the CRAMS and Polymers business into an independent listed entity' and granted in-principle approval for the same. Pursuant to this, the Parent incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025.
5 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and year to date figures up to third quarter of the financial year then ended as disclosed in the financial results for the year ended March 31, 2025.
Ig
| . Profit/(loss) fromcontinuing operations after exceptional items, before share |
||||
|---|---|---|---|---|
| of profit/(loss) of joint ventures and associate and tax | (116) | |||
| . Profit/(loss) from continuing operations before tax | (92) | |||
| ;. Profit/(loss) from continuing operations after tax | (67) | |||
| . Profit/{loss) from discontinued operations after tax | 18 | |||
| . Profit/(loss) for the period (5 + 6) | (49) | |||
| }. Total comprehensive income for the period | , | (79) | ||
| }. Paid-up equity share capital (Face value: f 10 per share) | 25s | |||
| 10. Other equity and Non-controlling interests | ||||
| 11, Securities premium account | L | 1,259 | ||
| 12. Net worth | , | 22,501 | ||
| 13. Outstanding debt | , | 7,072 | ||
| 14. Earnings per share | ||||
| ~ Basic and Diluted (for continuing operations) in = | (2.90) | |||
| - Basic and Diluted (for discontinued operations) in = | 0.71 | |||
| ~ Basic and Diluted (for continuing and discontinued operations) in = | 9.89 | (2.19) | ||
| 15. Debt equity ratio (no. of times) | 0.31 | 0.31 | ||
| 16. Debt service coverage ratio (no. of times) | 3.88 | 2.84 | ||
| 4AL | 2.39 | |||
| 17. Interest service coverage ratio (no. of times) Extracts of Statement of Standalone Audited for the quarter ended 30 June, 2025 |
Financial Resu | |||
| (®in crore) | ||||
| Particulars | Quarter ended |
Year ended |
||
| 30June, 2025 31 March, 2025 30 June, 2024 31 March, 2025 | ||||
| Not annualised | Annualised | |||
| . Revenue from continuing operations | 1,169 | 1,219 | 1,047 | 4,441 |
| . Profit from continuing operations before tax | 332 | 102 | 322 | |
| . Profit from continuing operations after tax | 307 | 7 | 256 | |
| . Profit from discontinued operations after tax | 18 | 15 | ||
| . Profit for the period (3 +4) | 115 | 271 | ||
| ;. Total comprehensive income for the period . Paid-up equity share capital (Face value: € 10 per share) |
i | 255 | (120) 255 |
|
| . Other equity | ||||
| . Securities premium account | 1,258 | 1,258 | 1,258 | |
| 10. Net worth | 18,974 | 18,194 | 18,223 | |
| 1,979 | 2,261 | 574 | 624 524 33 557 (149) 255 17,939 1,258 18,194 2,261 |
|
| - Basic and Diluted (for continuing operations) in = | 12.05 | 3.80 | 10.05 | 20.57 |
| - Basic and Diluted (for discontinued operations) in = | - | 0.71 | 0.59 | 1.30 |
| - Basic and Diluted (for continuing and discontinued operations) in& | 12.05 | 4.51 | 10.64 | 21.87 |
| 11, Outstanding debt 12. Earnings per share 13. Debt equity ratio (no. of times) |
0.10 | 0.12 | 0.03 | |
| 114, Debt service coverage ratio (no. of times) 15. Interest service coverage ratio (no. of times) |
19.29 5.40 |
5.23 4.69 |
27.20 18.08 |
0.12 13.86 5.68 |
Notes:
1, The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 July, 2025. 2. The above is an extract of the detailed format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 filed with the Stock Exchanges under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 is available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.tatachemicals.com). The same can be accessed by scanning the QR code provided below.
For and on behalf of the Board of
'TATA CHEMICALS LIMITED.
R, Mukundan Managing Director and CEO
TATA CHEMICALS LIMITED
Regd. Office : Bombay House, 24 Homi Mody Street, Fort, Mumbai - 400 001. Tel: +9122 66658282 Website: www.tatachemicals.com CIN:- L24239MH1939PLC002893 Emai [email protected]
| $\epsilon$ | मुंबई, शनिवार दि. २६ जुलै २०२५ | क्रीडा | कला | वित्रपट $\parallel$ | नाट्य | www.pratahkal.com पातःकाल |
|---|---|---|---|---|---|---|
從
SOLARA CIN: L24230MH2017PLC291636
Active Pharma Sciences नॉदणीकृत कार्यालय: 9वा मजला, सायबर वन, यूनिट क्र. 902, प्लॉट क्र. 4 आणि 6, सेक्टर 30ए, वाशी, नवी मुंबई - 400 703.
दूर. +91 22 2789 2924
कार्यालय: टीआयसीईएल बायो पार्क, 6वा मजला, मॉड्यूल क्र. 601, 602, 603, फेज 2, सीएसआयआर रोड, तारामणी, चेन्नई,
तमीळ नाडू–600113. दूर. +91 44 43446700 | फॅक्स: +91 44 47406190 | ई-मेल: [email protected]
ر 1925) अर्जून, 2025 रोजी तिमाहीकरीता संपलेले अलेखापरीक्षित एकत्रित वित्तीय निष्कर्षांचे संकलित विवरण
(प्रति शेअर डेटा वगळता रु. कोटीमध्ये)
| अ. क्र. |
तपशील | संपलेली तिमाही |
मागील संपलेली तिमाही |
मागील वर्षांतील संपलेली संबंधीत तिमाही |
मागील संपलेले आर्थिक वर्ष |
|---|---|---|---|---|---|
| 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 | ||
| अलेखापरीक्षित | टिप 5 पहा | अलेखापरीक्षित | लेखापरीक्षित | ||
| चालु असलेले संचालन | |||||
| एकूण उत्पन्न | 319.15 | 273.01 | 363.49 | 1,283.76 | |
| 2 | कालावधीसाठी करपूर्व निव्वळ नफा (अनन्यसाधारण बार्बीपूर्वी) | 10.52 | (2.10) | (13.46) | 0.54 |
| 3 | कालावधीसाठी करपूर्व निव्वळ नफा (अनन्यसाधारण बार्बीनंतर) | 10.52 | (2.10) | (13.46) | 0.54 |
| 4 | कालावधीसाठी करोत्तर निव्वळ नफा | 10.52 | (2.10) | (13.46) | 0.54 |
| 5 | कालावधीसाठी इतर सर्वसामावेशक उत्पन्न | (0.01) | (0.62) | (0.01) | 0.98 |
| 6 | कालावधीसाठी एकूण सर्वसामावेशक उत्पन्न (4+5) | 10.51 | (2.72) | (13.47) | 1.52 |
| 7 | समभाग भांडवल | 44.34 | 40.25 | 40.21 | 40.25 |
| 8 | इतर समभाग | 1,053.99 | |||
| 9 | प्रति समभाग प्राप्ती (प्रत्येकी रु. 10 चे) | ||||
| (संचालन सुरु ठेवण्याकरिता) – | |||||
| मूलभूत (रु.) | 2.46 | (0.93) | (3.50) | 0.14 | |
| सौम्यिकृत (रु.) | 2.46 | (0.93) | (3.50) | 0.14 | |
| टिपा: |
-
वरील माहिती म्हणजे सेबी (लिस्टिंग ॲण्ड ऑदर डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स, 2015 च्या रेग्युलेशन 33 अंतर्गत स्टॉक एक्स्वेंजेसमध्ये सादर केलेल्या तिमाहीसाठी वित्तीय निष्कर्षाचा
तपशीलवार विवरणाचा एक उतारा आहे. ति (www.bseindia.com) वर तसेच कंपनीची वेबसाईट (www.solara.co.in) वर उपलब्ध आहे. -
वरील सोलारा ॲक्टीव्ह फार्मा सायन्सेस लिमिटेड ("पालक" किंवा "दि कंपनी") आणि त्यांच्या उपकंपन्या (एकत्रितपणे "दि ग्रुप" म्हणून संदर्भित) च्या एकत्रित वित्तिय निष्कर्षांचे लेखापरीक्षण |
| समितीद्वारे पुनरावलोकन करण्यात आले होते व संचालक मंडळाद्वारे त्यांच्या दि. 25 जुलै, 2025 रोजी आयोजित सभेत त्यांना मंजुरी देण्यात आली आहे. दि. 30 जुलै, 2025 रोजी संपलेल्या तिमाहीकरिताच्या निष्कर्षांचे पुनरावलोकन हे डीलॉइट हस्किन ॲन्ड सेल्स एलएलपी – कंपनीचे वैधानिक लेखानि और केपनीच्या वैधानिक लेखापरीक्षकांनी 30 जुलै, 2025 रोजी |
|---|
| संपलेल्या तमािहीसाठी मर्यादित पुनरावलोकनाच्या संदर्भात एक अपरिवर्तित निष्कर्ष व्यक्त केले आहे. पालक, 09 मे 2024 च्या ऑफरच्या पत्राद्वारे रु. 10/- पर्यंत दर्शनी मूल्याचे इक्विटी शेअर रु. 1,19,98,755/- कंपनीच्या विद्यमान भागधारकांना रु. 375/- प्रति इक्विटी शेअर (प्रति रु. 365/- इक्विटी शेअर्सच्या शेअर प्रीमियमसह) प्रत्येक तीन इक्विटी शेअर्समागे एक इक्विटी शेअरच्या प्रमाणात योग्य आधारावर इक्विटीमध्ये एकूण रु. 449.95/- कोटी रक्कम रेकॉर्ड तारखेला म्हणजेच 15 मे 2024 रोजी शेअरधारक कंपनी कायद्याच्या कलम 62(1)(अ) आणि इतर लागू कायद्यांनुसार राइट इस्यू तयार करण्यात आला आहे. पालकांनी 19 जून 2024 रोजी देय असलेल्या 1,19,98,755 अंशत: देय इक्विटी शेअर्सची संख्या वाटप केली आहे. 26 मार्च 2025 रोजी, कंपनीने 1,19,98,755 अंशत: भरलेल्या राइट्स शेअर्ससाठी प्रति राइट्स शेअर (3.50 दर्शनी मूल्य आणि 127.75 शेअर प्रीमियम) रु. 131.25 च्या राइट्स इस्यू फर्स्ट कॉलला मान्यता दिली, असे 9 मे 2024 च्या लेटर ऑफ ऑफर अनुसार म्हटले आहे. फर्स्ट कॉल पेमेंट विंडो 16 एप्रिल 2025 ते 30 एप्रिल 2025 पर्यंत खुली होती. राइट्स इस्यू कमिटीने 6 मे 2025 रोजी 149.49 कोटी रुपयांच्या फर्स्ट कॉल मनीची नोंद घेतली आणि प्रति शेअर 3.5 रुपयांच्या 1,13,89,767 अंशत: भरलेल्या शेअर्सचे प्रति शेअर 7 रुपयांच्या अंशत: भरलेल्या शेअर्समध्ये रूपांतर करण्यास मान्यता दिली. फर्स्ट कॉल मनीमधून मिळालेल्या निव्वळ उत्पन्नापैकी, 115.00 कोटी रुपये कर्ज परतफेडीसाठी वापरले जातात, तर 23.27 कोटी रुपये ऑफर लेटरमध्ये नमूद केलेल्या वापराच्या अर्टीनुसार सामान्य |
| कॉर्पोरेट उद्देशांसाठी वापरले जातात. 4. कंपनीच्या संचालक मंडळाने 24 जानेवीरी 2025 रोजी झालेल्या बैठकीत सीआरएएमएस आणि पॉलिमर्स व्यवसायाचे विलगीकरण करन स्वतंत्र सूचीबद्ध संस्थेत रुपांतरण करण्याच्या प्रस्तावावर चर्चा केली आणि त्यासाठी तत्वत: मान्यता दिली. यानुसार, पालकांनी 29 एप्रिल 2025 रोजी सिंथिक्स ग्लोबल फार्मा सोल्युशन्स लिमिटेड ही पूर्ण मालकीची उपकंपनी स्थापन केली. 5. 31 मार्च, 2025 रोजी संपलेली तिमाहीचे आकडे हे 31 मार्च 2025 रोजी संपलेल्या संपूर्ण आर्थिक वर्षाच्या संदर्भात लेखापरीक्षित आकडे आणि 31 मार्च 2025 रोजी संपलेल्या आर्थिक वर्षाच्या तिसऱ्या तिमाहीपर्यंतच्या वर्ष–तारीख आकड्यांमधील संतुलन आकडे आहेत, जसे की 31 मार्च 2025 रोजी संपलेल्या वर्षाच्या आर्थिक निकालांमध्ये उघड केले आहे. |
| संचालक मंडळाच्या वतीने आणि साठी सही/- संदिप शशिकांत राव ठिकाण : बंगळुरू व्यवस्थापकीय संचालक आणि सीईओ दिनांक : 25 जुलै, 2025 डीआयएन क्र.: 10838251 |
प्रातःकाल मल्टीमीडीया लिमिटेडसाठी मुद्रक आणि प्रकाशक महीप गोयल यांनी हे दैनिक दांगट मीडिया प्रायदेड, २२, दीघे एमआयडीसी, टीटीसी इंडस्ट्रियल एरिया, दीघे, नवी मुंबई – ४००७०८ येथे छापून ५४३, लक्ष्मी प्लाजा, लक्ष्मी इंडस्ट्रियल इस्टेट, न्यू लिंक रोड, अंघेरी (प.) मुंबई- ४०००५३ येथे प्रसिद्व केले. संपादक-महीप गोयल. आरएनआयक्रमांक- MAHMAR/२०१४/५७२६० दूरध्वनी- २६३१९९२६ ई मेल- [email protected]